Drug intelligence / Profile preview

NTX-03

Development stage: Preclinical
Lead developer: Next Innovative Therapeutics
Modality: Small Molecules

Overview

NTX-03 is a nature-inspired, small molecule allosteric kinase inhibitor under development by Next Innovative Therapeutics (Nintx) for cardiometabolic indications, specifically heart failure, cardiac regeneration, and liver regeneration. The drug is designed to modulate kinase signaling pathways through an allosteric mechanism of action, promoting tissue repair and regeneration. NTX-03 is currently in the lead candidate stage of preclinical development.

Other names: NTX03NTX-03NTX 03

Targets

PK (Pyruvate kinase)

Beyond the preview

Go deeper on NTX-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTX-03.